Recon: Lilly to sell highest doses of Zepbound on its website; Supernus to acquire Sage for $795M

• Senators Propose Ban on Drug Advertising to Consumers (The Wall Street Journal)
• Sarepta reports second patient death after treatment with Duchenne gene therapy (STAT)
• RFK Jr.’s new vaccine panel raises questions of how Kennedy defines conflicts of interest (STAT)
• Kennedy allows US Senator Cassidy a pick in revamped CDC vaccine panel (Reuters)
• Lilly to offer highest doses of weight-loss drug Zepbound on website (Reuters)
• Lilly posts encouraging early-stage weight loss data on amylin candidate (Endpoints)
• Another round of consolidation is coming, FDA commissioner tells staff (Endpoints)
• Big Pharma's 10 highest-paid CEOs of 2024 (Fierce Pharma)
• Purdue Pharma $7.4 billion opioid settlement wins broad support from US states (Reuters)

• NextCure inks ADC deal with Shanghai drugmaker (Endpoints)
• US pharma bets big on China to snap up potential blockbuster drugs (Reuters)
• China Joins US in Brain Implant Race With Clinical Trial (Bloomberg)
• UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage (Pink Sheet)
• GSK applies to EU regulator for expanded use of RSV vaccine (Reuters)

• Supernus enters depression drug market with up to $795 million Sage deal (Reuters) (Endpoints)
• Gilead, Arcellx continue to spotlight safety of multiple myeloma cell therapy (Endpoints)
• Former CEO Anne Wojcicki wins bid for 23andMe (Endpoints)
• KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’ (Endpoints)
• FDA's oncology adcomm to review GSK's Blenrep relaunch plans (Endpoints)
• AbbVie says blood cancer drug fails late-stage trial (Reuters)
• Sixth Street-backed Caris lifts IPO price range, eyes $5.7 billion valuation (Reuters)
• AZ touts Ultomiris results in post-transplant complication trial (Fierce Pharma)
• Biogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness category (Fierce Pharma)

• Body Scan Makers Are Trying to Cash in on Obesity Drug Boom (Bloomberg)
• Centerline recalls guidewire over risk of coating being left in patients (MedTech Dive)
• Joint Commission, CHAI partner to develop guidance on health AI (MedTech Dive)
• Quest partners with MD Anderson to develop cancer risk blood test (MedTech Dive)
• Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist (MedTech Insight)
• Increasing Safety Concerns Spur Scrutiny of Device Plastics Use (MedTech Insight)
• Ellipsis Raises $45M To Expand AI Care Manager Across Health Systems (MedTech Insight)

• More states sign up for SNAP waivers (Food Dive)
• David responds to lawsuit, denies hoarding ingredient (Food Business News)
• HHS Budget Request Beats Familiar Drum (Food Safety)

• I’m a fertility doctor, and I think IVF needs more regulation (STAT)
• Hospitals would be hit hardest by Medicaid cuts in GOP tax bill, report finds (STAT)
• Don’t cut NIH and NSF budgets — let the government invest like a venture capitalist (STAT)
• With LDT Rule DOA, Could FDA Shift Focus To RUOs? (MedTech Insight)
• US FDA Teases Disclosure Program, But Industry Has Seen This Before (Pink Sheet)